?PPE BUYOUT? TOMDF could get to market first, which would be a huge relief for people at risk of severe symptoms upon contracting COVID-19 variants. If it weren’t for Merck and Todos, the market potential for Pfizer’s 3CL protease inhibitors would be clearer, but since the small company with fewer resources might hit the market faster, perhaps it would be best for Pfizer to join forces with Todos as it nears approval as Pfizer understands the molecular target and has the resources to push the drug forward. If TOMDF advances their trial quickly its possible that they could be rewarded with a buyout offer from PFE in this scenario.
News 
Market Data 
Discover 
